BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 11, 2025
Home » Newsletters » BioWorld

BioWorld

Dec. 7, 2021

View Archived Issues
Ionis Pharmaceuticals headquarters

Ionis collaborates with AZ in a deal potentially worth $3.6B

After struggling in the past year, Ionis Pharmaceuticals Inc. will collaborate with Astrazeneca plc to develop eplontersen for treating transthyretin amyloidosis, which is systemic, progressive and fatal. At stake for Ionis is $2.9 billion in potential sales-related milestone payments. Read More

Odyssey’s epic series A reaps $218M for ‘been there, done that’ dream team

Odyssey Therapeutics Inc. launched with a whopping $218 million series A round, the year’s second-largest, to fuel work by almost 100 employees recruited in the past few months, mostly from big pharma firms. Read More
Stock chart, upward arrow

Neuren’s stock rockets 91% on positive phase III results for trofinetide in Rett syndrome

PERTH, Australia – Neuren Pharmaceuticals Ltd.’s stock nearly doubled on positive top-line phase III results for trofinetide in Rett syndrome, meeting all primary and secondary endpoints in the pivotal phase III trial run by partner Acadia Pharmaceuticals Inc. Read More

Aiming to build a better ADC, Emergence raises $98M in series A

LONDON – Europe’s latest antibody-drug conjugate (ADC) specialist, Emergence Therapeutics AG, will be going head to head with pioneer Seagen Inc.’s approved ADC, Padcev, after raising €87 million (US$97.9 million) in a series A round. Read More
Dendritic cells

Adendra aims to exploit ‘yin and yang’ of dendritic cells with $53M series A funding

Life sciences VC Apple Tree Partners has launched its first U.K.-based portfolio company, providing $53 million in series A funding for immunology specialist Adendra Therapeutics Ltd. Read More

Medicago poised to seek approval for plant-based COVID-19 vaccine

Mitsubishi Tanabe Pharma Corp.'s Medicago Inc. plans to "imminently" seek Health Canada approval for its plant-based COVID-19 vaccine candidate, MT-2766, after top-line phase III results showed an overall vaccine efficacy rate of 71% against all variants of SARS-CoV-2. Read More
Gavel-and-scales.png

Former pharma exec charged with embezzlement

John Klein, the former CEO and majority shareholder of a New Jersey-based pharmaceutical company, was charged Dec. 6 with one count of wire fraud involving the alleged embezzlement of millions of dollars from the unnamed company. Read More

Promising results drive push for Paxlovid compulsory license

Although Pfizer Inc.’s COVID-19 oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), has yet to be authorized anywhere, the push for compulsory licensing of the drug has begun. Read More

Appointments and advancements for Dec. 7, 2021

New hires and promotions in the biopharma industry, including: Capsida, Corbus, Galderma, Gyroscope, Karyopharm, Metrion, Obsidian, Pepgen, Pharvaris, Revelation, Ventus. Read More

Financings for Dec. 7, 2021

Biopharmas raising money in public or private financings, including: Aditxt, Bavarian Nordic, Context, Mei, Metis. Read More

In the clinic for Dec. 7, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Acurx, Aeglea, Bavarian Nordic, Biohaven, Catalyst, Citius, Cyxone, Dydo, Glycomimetics, Hutchmed, Implicit, J&J, Karyopharm, Kazia, Kronos, Mediwound, Mesoblast, Nrx, Ocular, PDS, Ventyx, Xenon, ZZ. Read More

Other news to note for Dec. 7, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aerie, Alvotech, Anixa, Arbutus, Biovaxys Technology, Cancer Advances, Clover, Coda, Delix, Gain, Galderma, Hyundai, Glaxosmithkline, Hansa, Janone, Medison, Meryx, Molgenie, Novartis, Proteros Biostructures, Recursion, Roche, Santen, Scilex, Sosei, Sorento, Spago, Specific, Syndevrx, Taysha, Vickers, Vir, Vtv, X-Chem, Xcovery, XNK. Read More

Regulatory actions for Dec. 7, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cyprium, Enlivex, Gan & Lee, Octapharma, Roche, Sentynl, Theratechnologies, Vincerx. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 10, 2025.
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Brenig Therapeutics discovers new LRRK2 inhibitors

    BioWorld Science
    Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing